Autopsy report · NCT04120610

FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia

“Sponsor decision to terminate study prior to reaching full sample size.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 11 months before it stopped.
• 195 participants enrolled.
• Results were posted on the registry 2 years 5 months after it ended.

Vital statistics

Status

Terminated

Sponsor

Medtronic Endovascular

Sponsor type

Industry

Conditions

Peripheral Artery Disease

Interventions

FlowMet-R; ABI; TBI

Participants

195

Sites

5

Countries

United States

Trials that died the same way

• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (89% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (89% match in meaning)
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
  “Sponsor decision to terminate study.” (89% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (86% match in meaning)
• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
  “Business decision by sponsor to terminate the study” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.